Cense is a privately held company formed to launch therapeutic solutions, based on its unique formulation and release technology. Agglomerated Vesicle Technology (AVT) is a novel approach for delivering a broad range of therapeutics, with an intelligent and self-regulated mechanism for maintaining optimal patient-specific therapies. While AVT has utilities in a broad range of disease areas, the firm is focused on developing adaptive insulin delivery. Biodurance⢠Cense is developing an advanced, reformulated insulin therapy, Briodurance⢠for effective management of Type I and Type II Diabetes. It will have the unique ability to provide intelligent, automated release of insulin, during periods of high glucose (hyperglycemia). Most importantly, Briodurance⢠will be taken once daily and eliminate the need for multiple injections and monitoring, thereby promoting compliance and increasing quality of life. Therapeutic Focus: Diabetes One out of every six people in the U.S. has Type I, Type II, or pre-diabetes. 93% of all diabetics are non-compliant and are therefore at risk for heart disease, stroke, diabetic retinopathy, kidney disease, sciatica, etc. Current insulin treatments do not address the issue of compliance due mainly to limitations in technology and patient inconvenience. Existing insulin treatments are able to stabilize blood glucose levels, but must be constantly monitored, involve several injections a day, and ultimately have proved inadequate in maintaining normal glucose lev
